Working… Menu
Trial record 1 of 1 for:    ACE-CL-001
Previous Study | Return to List | Next Study

ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (Btk) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02029443
Recruitment Status : Active, not recruiting
First Posted : January 8, 2014
Last Update Posted : July 20, 2021
Information provided by (Responsible Party):
Acerta Pharma BV

No Study Results Posted on for this Study
Recruitment Status : Active, not recruiting
Actual Primary Completion Date : July 15, 2021
Estimated Study Completion Date : July 15, 2026
Publications automatically indexed to this study by Identifier (NCT Number):